Boston Scientific Corp. (BSX) Tops Q3 EPS by 6c; Adjusts FY11 Outlook, Guides Q411
Tweet
Share
E-mailGet Alerts BSX Hot Sheet
Price: $45.29 +0.76%
Revenue Growth %: +6.3%
Financial Fact:
Net income (loss) per common share - basic: 0.17
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +6.3%
Financial Fact:
Net income (loss) per common share - basic: 0.17
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Boston Scientific Corp. (NYSE: BSX) reported Q3 EPS of $0.15, $0.06 better than the analyst estimate of $0.09. Revenue for the quarter came in at $1.87 billion versus the consensus estimate of $1.91 billion.
Boston Scientific Corp. sees Q4 2011 EPS of $0.13-$0.16, versus the consensus of $0.10. Boston Scientific Corp. sees Q4 2011 revenue of $1.85-$1.95 billion, versus the consensus of $1.97 billion.
Boston Scientific Corp. sees FY2011 EPS of $0.67-$0.70, versus prior guidance of $0.64-$0.70 and the consensus of $0.45. Boston Scientific Corp. sees FY2011 revenue of $7.624-$7.724 billion, versus the consensus of $7.77 billion.
Boston Scientific Corp. sees Q4 2011 EPS of $0.13-$0.16, versus the consensus of $0.10. Boston Scientific Corp. sees Q4 2011 revenue of $1.85-$1.95 billion, versus the consensus of $1.97 billion.
Boston Scientific Corp. sees FY2011 EPS of $0.67-$0.70, versus prior guidance of $0.64-$0.70 and the consensus of $0.45. Boston Scientific Corp. sees FY2011 revenue of $7.624-$7.724 billion, versus the consensus of $7.77 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
- CarMax (KMX) Tops Q1 EPS by 35c, Beats on Revenue
- CarMax beats estimates as new strategy drives early results
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
